On September 7, 2016 Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, reported that clinical data for its lead drug candidate CB-839, the company’s novel, orally bioavailable glutaminase inhibitor, will be presented at the 28th Annual EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics, which is being held from November 29 to December 2, 2016 in Munich, Germany (Press release, Calithera Biosciences, SEP 7, 2016, View Source;p=RssLanding&cat=news&id=2200049 [SID:1234514965]). Clinical results to be presented in a plenary session will be focused on data from Calithera’s CB-839 Phase I combination trial with everolimus in renal cell carcinoma.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Phase 1 Study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients with clear cell and papillary renal cell carcinoma
Presenter: Funda Meric-Bernstam, M.D. Anderson Cancer Center
Plenary Session 2, Proffered Paper Session, Room 14
Wednesday, November 30, 2016, 4:30 p.m. CET
Two additional posters will be presented with preclinical results from CB-839 and the company’s novel metabolic immune checkpoint inhibitor CB-1158, respectively.
CB-839, a selective glutaminase inhibitor, has anti-tumor activity in renal cell carcinoma and synergizes with everolimus and receptor tyrosine kinase inhibitors
Presenter: Ethan Emberley, Calithera Biosciences
Poster Session: Molecular Targeted Agents II, Board P055
Thursday, December 1, 2016, 10:15 a.m.-5:00 p.m. CET
Arginase inhibitor CB-1158 elicits immune-mediated anti-tumor responses as a single agent and enhances the efficacy of other immunotherapies
Presenter: Suzanne Steggerda, Calithera Biosciences
Poster Session: Immunotherapy, Board P121
Wednesday, November 30, 2016, 10:15 a.m.-5:00 CET